Osimertinib

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor developed in-house, selectively targeting EGFR sensitizing mutations and the T790M resistance mutation while sparing normal cells.

Mechanism of Action

Osimertinib irreversibly binds the ATP-binding site of mutant EGFR, blocking downstream PI3K/AKT and MAPK signaling to induce tumor cell apoptosis. Its excellent blood-brain barrier penetration makes it effective for patients with CNS metastases.

Clinical Benefits

• Median PFS over 18 months in first-line treatment of EGFR-mutant advanced NSCLC
• Standard of care for T790M resistance
• Superior intracranial response rates in brain metastases

Dosing Information

Prescription only. Use under the guidance of physicians experienced in oncology. Refer to the approved package insert for dosage, contraindications and adverse reactions.